Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2025-01-26 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于股份回购进展情况的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from 特一药业集团股份有限公司 regarding the progress of its share repurchase program. It details the number of shares repurchased, prices, total funds used, compliance with regulatory rules, and future plans for repurchase. The document does not contain full financial statements or comprehensive financial analysis but focuses on the update of the company's share buyback activity. This matches the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buying back or selling its own shares. The document length is short (1335 characters), and it is not a report publication announcement or a certification. Therefore, the correct classification is POS with high confidence.
2025-01-26 Chinese
2024年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a "2024 年度业绩预告" which translates to "2024 Annual Performance Forecast" or "Earnings Forecast". It provides preliminary estimated financial results for the full fiscal year 2024, including net profit and earnings per share, with comparisons to the prior year. The document explicitly states that the data is preliminary, unaudited, and based on internal estimates, with final audited results to be disclosed in the 2024 Annual Report. The document is short (1281 characters) and serves as an announcement of expected financial performance rather than a full financial report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results highlighting key figures and outlook. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and detailed analysis. It is not a Report Publication Announcement (RPA) because it contains substantive preliminary financial data rather than just announcing a report's release. Therefore, the correct classification is Earnings Release (ER). FY 2024
2025-01-24 Chinese
2025年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2025 first extraordinary shareholders meeting of 特一药业集团股份有限公司. It includes information about the meeting date, voting methods, attendance, voting results for the election of independent directors, and legal opinions confirming the validity of the meeting and resolutions. This is a formal announcement of voting results from a shareholders meeting, not a full annual report, management report, or other financial report. The content matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 2062 characters, which is consistent with a detailed voting results announcement rather than a full report. Therefore, the correct classification is DVA with high confidence.
2025-01-23 Chinese
国浩律师（深圳）事务所关于特一药业集团股份有限公司2025年第一次临时股东会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality of the convening and procedures of a company's 2025 first extraordinary general meeting (临时股东会). It details the meeting's notice, attendance, voting procedures, and results, specifically the election of independent directors. The document is not a report of financial results, audit, or management discussion, but a legal certification of the shareholder meeting's compliance with laws and company bylaws. It is not an announcement of voting results per se, but a legal opinion on the meeting's legality. Given the nature of the document as a legal opinion on a shareholder meeting, it best fits under Regulatory Filings (RNS), which covers legal and compliance documents that do not fit other categories. The document length is short (3141 characters), and it is not a report publication announcement. Therefore, the classification is RNS with high confidence.
2025-01-23 Chinese
关于完成第五届董事会独立董事补选的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the completion of the election of independent directors to the company's board. It details the appointment of new independent directors, the resignation of previous ones, and their roles within board committees. There is no financial data, no mention of financial results, no audit information, no shareholder voting results, and no regulatory compliance filings. The content focuses solely on changes in the company's board of directors. Therefore, this document fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2025-01-23 Chinese
舆情管理制度（2025年1月）
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '舆情管理制度' (Public Opinion Management System) of 特一药业集团股份有限公司. It outlines the company's procedures and responsibilities for managing public opinion, media reports, and crisis communication related to the company. It includes organizational structure, reporting processes, response principles, and confidentiality obligations. There is no financial data, no mention of financial results, no shareholder meeting materials, no legal proceedings, no capital changes, no voting results, and no regulatory filings or announcements. The document is a governance-related internal policy document describing the company's governance practices regarding public opinion and crisis management. Therefore, it fits best under Governance Information (CGR). The document length is 3120 characters, which is relatively short but contains substantive governance content, not just an announcement or certification. Hence, the classification is CGR with high confidence.
2025-01-20 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.